Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 125 participants.
Also called NCT03604198
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT03604198 -
2024-514079-17-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Austria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03604198. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-07 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- Condition
- Cushing Syndrome
- Intervention (Drug)
- relacorilant
- Lead sponsor
- Corcept Therapeutics
Record details
- Record id
cardio:ct-nct03604198- Content hash
c6ce9352e18b535516f7cd5dc1d31d58113784a2700d1622b36eb9a1ebe94872